PDA

View Full Version : D-bol ,Test Sus, cynomel



815_4_life
06-20-2002, 12:28 AM
I am jump starting my cycle by taking the d-bol a few days before I start my test sus. 600mg. a week, w/ cynomel (if thats what you suggest) ,nolvadex incase, clomid ready for end of cycle, or should I just take the nolvadex during the cycle because how many side effects are with cynomel? 50mg is too much of d-bol a day, but I only have the 50mg tabs, just cut in half and do 25mg?

thanks

Gear101*
06-20-2002, 07:09 AM
well bro it's up too you.. what i like to do is wait until side show up then start the Nolv and from this cycle on i'm using Liq and not nolv.. most people think running nolv through out your cycle hurts gains.. there no resaerch studies that show that but IMO..

and go to www.getpinz.com and get a pill cutter or use a razor blade to cut those little suxer.. hope that helps

815_4_life
06-20-2002, 09:19 AM
thanks bro, i have a pill cutter

DecaDent*
06-20-2002, 11:19 AM
Originally posted by Gear101*
.. most people think running nolv through out your cycle hurts gains.. there no resaerch studies that show that but IMO..


Gear101,here's one,I actually have a bunch of studies on this,they deal primarily in cancer research but the effects are applicable to athletes. Tamoxifen is generic for Nolva.

Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.

OBJECTIVE: Tamoxifen suppresses insulin-like growth factor-1 (IGF-1) plasma levels in early and advanced breast cancer patients. Relationships between tamoxifen (GH) and IGF-1 are complex and not completely described yet. The present investigation was performed to evaluate the effect of acute and chronic tamoxifen administration on GH response to growth hormone-releasing hormone (GHRH), as well as on IGF-1 serum levels. MATERIALS AND METHODS: Evaluation of GH after administration of GHRH was performed (a) at baseline, (b) 3 hours after 20 mg oral administration of tamoxifen and (c) after 12 weeks of 20 mg a day oral tamoxifen treatment, in fifteen postmenopausal stage I-II breast cancer patients. IGF-I was measured at baseline and after chronic tamoxifen administration. RESULTS: The GH response to GHRH was significantly reduced after 12 weeks of tamoxifen 10 mg administered twice a day orally (mean peak 3.2 +/- 0.2 micrograms/l, mean AUC 261.3 +/- 18.2 micrograms/minute p < 0.01 versus basal AUC). A concomitant significant reduction of IGF-1 was observed after 3 months of tamoxifen treatment. Basal pretreatment levels of 113.2 +/- 15.5 micrograms/l were suppressed to 70 +/- 7.9 micrograms/l (p < 0.01). CONCLUSION: Our study confirm the inhibitory effect of tamoxifen on IGF-I and suggested, as shown in previous in vitro data, that its suppression could be directly related to GH reduction in response to GHRH stimulation.


Anticancer Res 2001 Jan-Feb;21(1B):585-8 (ISSN: 0250-7005)
Mandala M; Moro C; Ferretti G; Calabro MG; Nole F; Rocca A; Munzone E; Castro A; Curigliano G
Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141-Milan, Italy. mario.mandala@ieo.it